Nausea and Vomiting
4
Pipeline Programs
3
Companies
3
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
2
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
VP
Competitive Landscape
3 companies ranked by most advanced pipeline stage
VP
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Bausch HealthCesamet
Vanda PharmaceuticalsTradipitant
Heron TherapeuticsAPF530
Clinical Trials (3)
Total enrollment: 280 patients across 3 trials
A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting
Start: Aug 2006Est. completion: Dec 2007
Phase 4Terminated
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
Start: Feb 2026Est. completion: Dec 2026280 patients
Phase 3Not Yet Recruiting
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Start: Jun 2006Est. completion: Feb 2009
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space